Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Pyrotech Closes $97 Million Round to Develop Novel Technology for Autoimmune and Cancer Drugs

publication date: Jul 27, 2023

Beijing’s Pyrotech Therapeutics completed an impressively large $97 million Series A funding to develop novel small molecule drugs that modulate immune responses for autoimmune diseases and cancer. The company identifies molecules that inhibit excessive and harmful immune reactions in autoimmune diseases while also developing molecules that can exaggerate pyroptosis, a type of cell death caused by stimulating strong immune responses, to eradicate tumors. Pyrotech was founded in early 2021 by Professor Feng Shao of the National Institute of Biological Sciences, Beijing, and Dr. TJ Deng, formerly the CEO of BioDuro China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital